Abstract:T-Antigen (Gal-beta1,3-GalNAc-alpha-O-Ser/Thr) is an important precursor of mucin-type O-glycans. T-Antigen is found to be closely associated with cancer progression and metastasis and has been used to develop carbohydrate-based anticancer vaccines. Enzymatic synthesis of T-antigen disaccharides have relied on the use of beta-1,3-galactosyltransferases recently cloned and characterized from several eukaryotic organisms. However, its application is limited by the difficulty of obtaining homogeneous enzymes and the strict substrate specificity of enzymes. Recently, a number of bacteria have been found to express carbohydrate structures that mimic host glycans. The corresponding glycosyltransferases have been exploited in the facile synthesis of a number of clinically important glycoconjugate mimics. In this study, we biochemically characterized a bacterial beta-1,3-galactosyltransferase (WbiP) from Escherichia coli O127, which expresses a T-antigen mimic in the lipopolysaccharide (LPS) structure. Substrate study showed that WbiP could readily glycosylate a series of N-acetylgalactosamine (GalNAc) analogues with alpha-substitutions at the reducing end, including glycosylated Ser and Thr (GalNAc-alpha-O-Ser/Thr), which illustrates the use of WbiP for the facile synthesis of T-antigens. Alignment of a group of putative bacterial beta-1,3-galactosyltransferases revealed the presence of two conserved DXD motifs, possibly suggesting a different functional role of each motif. Site-directed mutagenesis, enzyme kinetics as well as UDP-bead binding assays were carried out to investigate the role of each DXD motif in WbiP. The results suggest that 88DSD90 is critical in the binding of sugar donor UDP-Gal, whereas 174DYD176 may participate in the binding of the sugar acceptor. This study expands the scope of using bacterial glycosyltransferases as tools for in vitro synthesis of glycoconjugate mimics with clinical significance.

Rational Design of Dual-Domain Binding Inhibitors for N-Acetylgalactosamine Transferase 2 with Improved Selectivity over the T1 and T3 Isoforms

Characterization of a Bacterial Beta-1,3-galactosyltransferase with Application in the Synthesis of Tumor-Associated T-antigen Mimics.

Rational Design of Cell Active C2-modified DGJ Analogues for the Inhibition of Human Α-Galactosidase A (GALA).

Synthesis and Evaluation of the Analogues for Galactosyl Donors As Inhibitors Of-1,4-Galactosyltransferase

Potent and Selective Cell-Active Iminosugar Inhibitors of Human Α-N-acetylgalactosaminidase (Α-Nagal).

An unusual dual sugar-binding lectin domain controls the substrate specificity of a mucin-type O-glycosyltransferase

Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc‐Transferase

Synthesis and Biological Activities of Amino Acids Functionalized Α-Galcer Analogues.

Functional control of polypeptide GalNAc-transferase 3 through an acetylation site in the C-terminal lectin domain

Design and Synthesis of Naphthalimide Group-Bearing Thioglycosides As Novel Β-N-acetylhexosaminidases Inhibitors.

Modification of the Thioglycosyl-Naphthalimides As Potent and Selective Human O-GlcNAcase Inhibitors.

Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels

Catalytic and glycan-binding abilities of ppGalNAc-T2 are regulated by acetylation

Ligand conjugate SAR and enhanced delivery in NHP

Synthesis of α‐Hydroxy‐1,2,3‐Triazole‐linked Sialyltransferase Inhibitors and Evaluation of Selectivity Towards ST3GAL1, ST6GAL1 and ST8SIA2

Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug design

Selective Inhibition of Β-N-acetylhexosaminidases by Thioglycosyl–naphthalimide Hybrid Molecules

An acetylation site in lectin domain modulates the biological activity of polypeptide GalNAc-transferase-2

Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein

Nanomolar β-glucosidase and β-galactosidase inhibition by enantiomeric α-1- C -alkyl-1,4-dideoxy-1,4-imino-arabinitol derivatives

Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient